NASDAQ:XCUR Exicure Q4 2024 Earnings Report $1.74 -0.01 (-0.57%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$1.72 -0.02 (-1.15%) As of 07/28/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Exicure EPS ResultsActual EPS-$3.39Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AExicure Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AExicure Announcement DetailsQuarterQ4 2024Date3/18/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsExicure's next earnings date is estimated for Friday, August 7, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Exicure Earnings HeadlinesExicure Reaches Preliminary Settlement in Derivative LawsuitsJuly 9, 2026 | theglobeandmail.comExicure Announces Board and Committee ChangesJune 30, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 11, 2026 | finanznachrichten.deExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementJune 10, 2026 | markets.businessinsider.comExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 10, 2026 | globenewswire.comSee More Exicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email. Email Address About ExicureExicure (NASDAQ:XCUR) is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system. The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology. By leveraging the unique structural properties of SNA constructs, Exicure aims to improve cellular uptake, enhance pharmacokinetics and reduce off‐target effects compared with traditional nucleic acid therapies. Founded on technology originating from Northwestern University, Exicure is headquartered in Skokie, Illinois, where it conducts its research, preclinical studies and early‐stage development activities. The company completed its initial public offering on the Nasdaq exchange under the ticker XCUR and maintains a focused R&D footprint in the Chicago area. Exicure collaborates with academic institutions and biopharmaceutical partners to advance its SNA platform and expand its therapeutic reach. Guided by a management team with deep expertise in biotechnology innovation, the company is working to translate its nanotechnology into novel treatments for patients with high‐unmet medical needs around the world.View Exicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Stocks Have Soared in 2026—Can They Keep Climbing?Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy StoryRambus: Another AI Phoenix Ready to Rise From the Ashes of CorrectionAmkor Sells Off After Earnings—Why Weak Guidance Isn't the Real StoryWestern Digital’s Earnings Will Test Whether Its AI Rally Has More RoomIs the Market Mispricing ServiceNow's AI Future?Whirlpool’s Report May Show How Frozen the Housing Market Really Is Upcoming Earnings Ferrari (7/30/2026)Air Products and Chemicals (7/30/2026)ArcelorMittal (7/30/2026)Vale (7/30/2026)Mastercard (7/30/2026)Apple (7/30/2026)ASE Technology (7/30/2026)Monolithic Power Systems (7/30/2026)CRH (7/30/2026)Quanta Services (7/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
